From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. Women's Health>
  4. Summary and Comment

Glyburide Outperformed Metformin in Treating Women with Gestational Diabetes

Compared with glyburide, metformin was associated with doubled risk for poor glycemic control.

Gestational diabetes (GDM) affects about 4% of pregnancies. Insulin is standard therapy for GDM that is not controllable by diet; the optimal oral agent to control blood glucose, however, is unknown. Investigators in New Mexico randomized 149 GDM patients (86% Latina) to metformin or glyburide and compared the medications' efficacy in maintaining glycemic control (defined as fasting blood glucose ≤105 mg/dL and 2-hour postprandial glucose ≤120 mg/dL).

Participants who received glyburide were more than twice as likely to achieve glycemic control than were metformin users (35% vs. 16%; odds ratio, 2.7). However, mean birth weight of infants in the metformin group was lower than that of glyburide infants (P=0.02). Incidence of preeclampsia, maternal hypoglycemia, and fetal macrosomia was similar in both groups.

Comment: These results show that glyburide provides better control of blood glucose than does metformin; however, the study's small size limits our ability to compare secondary outcomes (e.g., neonatal outcomes, cesarean delivery rate). In addition, results might not be generalizable to all patients, given that the vast majority of participants in this study were Latina. Although the possible effects of ethnicity on the results are unknown, the failure rate of metformin is consistent with that observed in the Metformin in Gestational Diabetes Trial (JW Womens Health May 7 2008). The authors note that the lower birth weights in the metformin group might reflect the potential benefits of metformin as an insulin sensitizer that can cross the placenta. Because patients are more likely to prefer and adhere to oral treatment of GDM, an oral medication for effective control of blood glucose during pregnancy would be highly desirable. If larger studies confirm these results, glyburide could be the oral agent of choice for treatment of women with GDM.

Wendy S. Biggs, MD

Published in Journal Watch Women's Health January 14, 2010

Citation(s):

Moore LE et al. Metformin compared with glyburide in gestational diabetes: A randomized controlled trial. Obstet Gynecol 2010 Jan; 115:55.

Reader Remarks:

Review and add to remarks on this article

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

The editors of Journal Watch may respond to Reader Remarks, but we cannot promise to respond to a particular remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Related Content

Sign-In

Forgot your password? Login via Athens
or your institution

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2010. Massachusetts Medical Society. All rights reserved.